Want to see FR:BVI full AI Analyst Report?
BVI Stock Chart & Stats
€26.98
€0.24(0.89%)
At close: 4:00 PM EDT
€26.98
€0.24(0.89%)
Day’s Range― - ―
52-Week Range€24.58 - €30.18
Previous CloseN/A
Volume159.98K
Average Volume (3M)1.08M
Market Cap
€12.27B
Enterprise Value€14.13K
Total Cash (Recent Filing)€942.10M
Total Debt (Recent Filing)€3.04B
Price to Earnings (P/E)24.3
Beta0.92
Next Earnings
Feb 25, 2027EPS Estimate
0.91Next Dividend Ex-DateN/A
Dividend Yield3.33%
Share Statistics
EPS (TTM)1.14
Shares Outstanding453,871,520
10 Day Avg. Volume713,778
30 Day Avg. Volume1,078,337
Financial Highlights & Ratios
PEG Ratio4.32
Price to Book (P/B)7.08
Price to Sales (P/S)1.87
P/FCF Ratio14.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.21Price Target Upside19.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)1.53
Revenue Forecast (FY)€6.72B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationFree cash flow of ~€820M (2025) and operating cash flow near ~€967M demonstrate durable internal funding. Consistent cash generation supports capex, dividends and debt servicing, giving the company financial resilience and strategic optionality over the next several quarters.
Regulation-driven Recurring ModelMany services are contract- and regulation-driven (inspections, surveillance audits, re-certifications) and BV has global accreditations. This creates sticky, predictable revenue and pricing leverage across end markets, supporting durable revenue visibility and customer retention.
Durable Profitability & Steady GrowthMulti-year revenue expansion with net margins around 8–9% and operating margin ~14% (2025) indicates operational strength. Consistent profitability underpins reinvestment capacity and sustained free cash flow, reinforcing long-term business stability and execution.
Bears Say
Elevated, Rising LeverageRising debt and a debt-to-equity around 2.01x—combined with a year-over-year equity decline—reduce financial flexibility. Elevated leverage increases refinancing and interest-rate risk and could constrain capital allocation, deleveraging ability, or opportunistic investments.
Gross Margin VolatilityNoted gross margin variability, including an unusually low 2025 gross margin, signals mix shifts or cost control inconsistency. Variable gross margins make long-term margin sustainability less predictable and complicate reliable forecasting of operating profit.
Cash-conversion Drag Vs ProfitCoverage of operating profit by cash flow below 0.5 suggests working-capital or timing issues that limit conversion of accounting profits into liquid resources. That dampens the pace at which profits can be used for deleveraging or reinvestment despite healthy headline FCF.
Bureau Veritas News
BVI FAQ
What was Bureau Veritas’s price range in the past 12 months?
Bureau Veritas lowest stock price was €24.58 and its highest was €30.18 in the past 12 months.
What is Bureau Veritas’s market cap?
Bureau Veritas’s market cap is €12.27B.
When is Bureau Veritas’s upcoming earnings report date?
Bureau Veritas’s upcoming earnings report date is Feb 25, 2027 which is in 205 days.
How were Bureau Veritas’s earnings last quarter?
Bureau Veritas released its earnings results on Jul 29, 2026. The company reported €0.68 earnings per share for the quarter, beating the consensus estimate of €0.67 by €0.01.
Is Bureau Veritas overvalued?
According to Wall Street analysts Bureau Veritas’s price is currently Undervalued.
Does Bureau Veritas pay dividends?
Bureau Veritas pays a Annually dividend of €0.92 which represents an annual dividend yield of 3.33%. See more information on Bureau Veritas dividends here
What is Bureau Veritas’s EPS estimate?
Bureau Veritas’s EPS estimate is 0.91.
How many shares outstanding does Bureau Veritas have?
Bureau Veritas has 453,871,520 shares outstanding.
What happened to Bureau Veritas’s price movement after its last earnings report?
Bureau Veritas reported an EPS of €0.68 in its last earnings report, beating expectations of €0.67. Following the earnings report the stock price went up 7.138%.
Which hedge fund is a major shareholder of Bureau Veritas?
Currently, no hedge funds are holding shares in FR:BVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bureau Veritas
Bureau Veritas S.A., a French company, delivers a broad spectrum of global testing, inspection, and certification (TIC) services. Its core mission is to guarantee that products, assets, and management systems meet either mandatory regulations or voluntary industry benchmarks. This is achieved through detailed inspection, analytical assessments, auditing, and certification processes, leading to comprehensive compliance reports. The company offers specialized laboratory and on-site testing for manufacturing and processing industries, alongside inspection services aimed at confirming product quality, quantity, and adherence to regulatory requirements. Additionally, it provides certifications for management systems, specific products, and even individuals. The firm's activities are organized into six distinct divisions: Marine & Offshore; Agri-Food & Commodities; Industry; Buildings & Infrastructure; Certification; and Consumer Products. Bureau Veritas caters to an exceptionally diverse clientele, spanning numerous sectors including automotive, transportation, construction, chemicals, agriculture, consumer products, food, marine, offshore, oil and gas, power, utilities, financial services, and governmental organizations. Established in 1828 and headquartered in Neuilly-sur-Seine, France, the company boasts an extensive international presence, operating approximately 1,600 offices and laboratories across about 140 countries.
BVI Stock 12 Month Forecast
Average Price Target
€32.21
▲(19.37% Upside)
Technical Analysis
bioMerieux
―
Eurofins Scientific
―
ID LOGISTICS
―
Sartorius Stedim Biotech
―
SPIE SA
―








